Loading…
Based on limited available metadata, this FDA Warning Letter was issued to Lupin Limited, a pharmaceutical manufacturer, on September 10, 2019. The letter addresses unspecified drug manufacturing or compliance violations, though the specific nature of the violations cannot be determined from the metadata provided. This warning falls under FDA's drug product regulatory authority, though the specific issuing office is not identified in the available information. Without access to the full letter text, the precise regulatory concerns and required corrective actions remain undetermined.